Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates
Open Access
- 27 March 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1332458
Abstract
Eravacycline (ERV) has emerged as a therapeutic option for the treatment of carbapenem-resistant pathogens. However, the advent of heteroresistance (HR) to ERV poses a challenge to these therapeutic strategies. This study aimed to investigate ERV HR prevalence among common clinical isolates and further characterize ERV HR in carbapenem-resistant Klebsiella pneumoniae (CRKP). A total of 280 clinical pathogens from two centers were selected for HR and analyzed using population analysis profiling (PAP) and modified E-tests. The PAP assay revealed an overall ERV HR prevalence of 0.7% (2/280), with intermediate heterogeneity observed in 24.3% (68/280) of strains. The proportion of heteroresistant strains was 18.3% according to modified E-test results. A time-killing assay demonstrated that CRKP CFU increased significantly after 10 h of ERV treatment, contributing to the reduced bactericidal effect of ERV in vitro. Interestingly, dual treatment with ERV and polymyxin B effectively inhibited the total CFU, simultaneously reducing the required polymyxin B concentration. Furthermore, fitness cost measurements revealed a growth trade-off in CRKP upon acquiring drug resistance, highlighting fitness costs as crucial factors in the emergence of ERV HR in CRKP. Overall, the findings of the current study suggest that ERV HR in clinical strains presents a potential obstacle in its clinical application.Keywords
This publication has 39 references indexed in Scilit:
- Heteroresistance to cefepime–taniborbactam in metallo-β-lactamase-encoding EnterobacteralesThe Lancet Infectious Diseases, 2023
- RecA inactivation as a strategy to reverse the heteroresistance phenomenon in clinical isolates of Escherichia coliInternational Journal of Antimicrobial Agents, 2023
- Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedsideClinical Microbiology and Infection, 2022
- Cefiderocol heteroresistance in Klebsiella pneumoniae is linked to mutations in the siderophore receptor cirA and β-lactamase activitiesInternational Journal of Antimicrobial Agents, 2022
- Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort studyThe Lancet Infectious Diseases, 2022
- Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogensThe Lancet Infectious Diseases, 2021
- Eravacycline: A Review in Complicated Intra-Abdominal InfectionsDrugs, 2019
- In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015Diagnostic Microbiology and Infectious Disease, 2018
- Review of Eravacycline, a Novel Fluorocycline Antibacterial AgentDrugs, 2016
- BreakDancer: an algorithm for high-resolution mapping of genomic structural variationNature Methods, 2009